Defence Science

Defence Therapeutics is a Canadian clinical-stage biotechnology company focused on developing the next generation of vaccines and antibody-drug conjugates (ADCs) for cancer and infectious diseases. The company's core technology is the Accum platform, which is designed to enhance the intracellular delivery of biological molecules by facilitating their escape from endosomes directly into the cytosol or nucleus. This platform is being applied to develop highly potent ADCs, more effective DNA/RNA vaccines, and novel cancer cell therapies. By improving the precision and efficiency of drug delivery, Defence Therapeutics aims to overcome common limitations in current immunotherapy and oncology treatments.